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ABSTRACT 
 
Objectives :  In November 2014 the CMDh (a regulatory body representing EU Member States) 
advised doctors not to prescribe sodium valproate for epilepsy or bipolar disorder in pregnant 
women, in women who can become pregnant or in girls unless other treatments are ineffective or 
not tolerated. This study aimed to determine if there is any evidence that this warning led to 
changes in prescription patterns of sodium valproate and other anti-epileptic drugs (AEDs)  in 
women of childbearing age.  
 
Design and setting : Cohort of 5.4 million women aged between 10 and 50 years identified in 
electronic health care data from United Kingdom, France, and Italy (2007–2016). 
 
Main Outcome Measures : Anti‐epileptic drug (AED) prescriptions. 
 
Results: The prevalence of women receiving AED prescriptions in 2016 varied from 12.2 per 1000 to 
29 per 1000 in the four regions. The incidence of prescribing any AED (excluding clonazepam, 
gabapentin and pregabalin – medications not commonly prescribed for epilepsy) fell in all regions 
each year on average by 7.5% (95%CI : 7.0% to 8.0%) (Emilia Romagna) , 9.6% (8.3% to 11.0%) 
(France ) , 7.1% (6.7% to 7.6%) (Tuscany) and 0.4% (0.2% to 1.0%) (UK). The relative odds of 
prescribing sodium valproate rather than any other AED (excluding clonazepam, gabapentin and 
pregabalin) decreased more from 2014 to 2016 compared to 2007 to 2013 in France (OR= 0.77 
(95%CI: 0.60 to 0.98)), Tuscany (0.81 (0.76 to 0.86)), Emilia Romagna (0.83 (0.76 to 0.90)) and the UK 
(0.92 (0.80 to 1.06; not statistically significant).  
 
Conclusions : There is evidence that the CMDh warning in 2014 did lead to changes in prescription 
patterns of sodium valproate  in women of childbearing age. There were considerable differences in 
prescribing practice amongst regions of Europe.  
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Section 1: What is already known on this topic 
 Sodium valproate exposure during the first trimester is associated with the occurrence of 
congenital anomalies and also neurodevelopmental delays 
 The European Medicines Agency sent warnings to health care professionals to limit sodium 
valproate prescriptions to women for whom other alternatives are not possible and to 
inform patients of the risks in November 2014. 
 It is unknown if these warnings have any effect on prescribing patterns in Europe 
 
  
Section 2: What this study adds 
 Prescription rates for sodium valproate compared to other anti-epileptic medications did fall 
after warnings were sent to health care professionals in 2014 
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INTRODUCTION 
Antiepileptic drugs (AEDs) are a diverse class of medicines that are prescribed for an increasing 
number of indications including epilepsy, bipolar disorder, migraine prophylaxis and neuropathic 
pain.[1-3] AEDs are commonly prescribed to women of childbearing age[4-9] and the prevalence of 
prescribing varies by geographic location[9, 10]. The chronic and serious nature of some of the 
indications for which they are prescribed means that it is not always possible for women to 
discontinue their treatment in advance of and during pregnancy.[11-13] For some time there has 
been evidence that certain AEDs, when taken by women during their pregnancy, are associated with 
a two- to three-fold increase in risk of major congenital malformations in the offspring.[14-17] The 
risk varies by AED, with sodium valproate often reported as having the highest risk[14] and 
lamotrigine and levetiracetam the lowest risk,[17] although for many of the other newer AEDs the 
number of exposures during pregnancy available for study is low. In recent years there has been a 
growing body of evidence of negative neurodevelopmental outcomes in children exposed to sodium 
valproate in-utero [14, 18-23]. 
 
In October 2013, the Medicines and Healthcare Regulatory Authority (MHRA) issued a referral into 
the use of sodium valproate in girls and women of childbearing potential. Following completion of 
the review by the Pharmacovigilance Risk Assessment Committee (PRAC) in the European Medicines 
Agency (EMA), the CMDh (a regulatory body representing EU Member States) strengthened 
warnings on the use of sodium valproate in women and girls due to the risk of malformations and 
developmental problems in babies exposed to sodium valproate in the womb. The warnings aim to 
ensure that patients are aware of the risks and that they take sodium valproate only when clearly 
necessary. The CMDh review resulted in a personal letter being sent to all healthcare professionals 
in all European countries in December 2014 informing them of the changes in the recommendations 
for valproate prescribing.   
 
This study, capturing data from three European countries, aimed to determine if there is any 
evidence that warnings about the harm of sodium valproate to the fetus have led to changes in 
prescription patterns of sodium valproate and other AEDs in women of childbearing potential.   
 
METHODS 
 
Electronic healthcare databases from within four regions/countries contributed data to the study: 
the United Kingdom (UK-wide Clinical Practice Research Datalink (CPRD)), France (Echantillon 
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Generaliste des Beneficiaires (EGB)): French Health Insurance System and Hospital Medical 
Information Systems (PMSI)), Emilia Romagna in Italy (Certificate of Delivery Assistance (CeDAP) and 
Emilia Romagna Prescription Database (ERPD)) and Tuscany in Italy (CeDAP, Hospital Discharges 
Registry and Tuscany Prescription Database (TPD)). An overview of the databases can be found in 
Table 1 and has been reported elsewhere.[24] Ethical and data access approvals were obtained for 
each database from the relevant governance infrastructures. The protocol was registered in the 
ENCePP PAS register (EUPAS21171). 
 
Study population 
A common protocol was used to extract data from all databases. The study period ran from 1 
January 2007 until 31 December 2016. The source population consisted of all females in each 
database who were aged between 10 and 50 years at some point during the study period. Eligible 
females were required to have contributed a minimum of 365 days to the database. 
 
Exposure 
The exposures of interest were AEDs with an anatomical therapeutic chemical (ATC) code starting 
N03A and also clobazam (ATC N05BA09) which is licensed for epilepsy in the countries under study. 
Sodium valproate included both prescriptions for valproic acid and for valpromide. All AED 
prescriptions that were issued in the United Kingdom or dispensed in France and Italy to any female 
during her time in the study cohort were identified. In all four regions there was a large proportion 
of women with only a single AED prescription during the entire time they were in the study (38% in 
France, 31% in Emilia Romagna, 28% in Tuscany and 22% in the United Kingdom). Around 75% of 
these women were prescribed gabapentin, pregabalin or clonazepam in France, the UK and Emilia 
Romagna (54% in Tuscany). These three medications are often prescribed for neuropathic pain 
rather than epilepsy.  Given the fact that AEDs are mostly associated with chronic treatment, 
irrespective of indication, it was decided that only females issued/dispensed more than 1 
prescription for an AED during their time in the study cohort were defined as exposed. Sensitivity 
analysis including all women were performed. 
 
A cohort of first-ever AED users was identified within the AED exposed cohort. ‘First-ever users’ 
were defined as those who received an AED prescription during the study period who had been in 
the database for >365 days prior to the date of their first AED prescription without any other AED 
prescribing during this time. 
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For each female receiving an AED attempts were made to determine the indication for the AED 
prescribing. In all databases, this involved the creation of a unique database specific algorithm to 
utilise all available information which included some or all of the following: medical diagnoses, 
hospital discharge data, special reimbursement status or exemption codes, information on the type 
of prescriber, the specific name of the medicine and co-prescribing of other medicines such as 
psychotropic drugs.  In Italy a modified version of the algorithm developed by Naldi et al  was 
used[25], because the original algorithm did not attempt to determine prescribing for migraines or 
pain. The level of detail available varied between databases with the main aim being to distinguish 
between prescribing for epilepsy and prescribing for psychiatric conditions (such as bipolar disorder 
or anxiety) or pain (neuropathic pain or migraine).  
 
Patient and Public Involvement 
This research was done without patient involvement.  Patients were not invited to comment on the 
study design and were not consulted to develop patient relevant outcomes or interpret the results. 
Patients were not invited to contribute to the writing or editing of this document for readability or 
accuracy. 
 
ANALYSIS 
The analyses were carried out separately for each database at the host institution and shell tables of 
aggregated results were then provided to the lead institution to be compiled. The prevalence of AED 
prescribing in females of childbearing age was calculated per 1000 female population with 95% 
confidence intervals (CI95) for 2016 using the Poisson distribution. The ten most common AEDs in 
2016 were identified according to the prevalence in each region, with each region having the same 
weight (despite the differences in population sizes).  
 
The annual change in incidence of AED prescribing in first-ever users was analysed using Poisson 
regression separately for each region. To determine if there was a change in the odds of prescribing 
sodium valproate rather than another AED from 2014 onwards an interrupted time series logistic 
regression model was fitted using segmented regression assuming that the change will be a gradual 
change in the gradient of the trend starting in 2014. This means that two straight lines are fitted: one 
from 2007 to 2014 and one from 2014 to 2016. A sensitivity analysis was performed including 
women who had only one AED prescription during the study period. The incidence of AED 
prescribing was also stratified by age at first prescription in the categories: < 20 years old, 20-29 
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years old, 30-39 years old and 40+ years old. For France the incidence of AED prescribing was also 
stratified by indication.  
 
There was considerable missing data on the indication for AED prescribing. This variable was only 
analysed for France wen there was sufficient information available and the “other/unknown” 
outcome was identified on the table. OTHER COMMENTS ON MISSING DATA RACHEL ??? 
 
All analyses were performed using STATA 14. 
 
RESULTS 
Data were available from the four regions on a total of 5.4 million women from 2007-2016. The 
number of females captured in the databases in each region differed in size from the UK with 2.4 
million women, Emilia Romagna with 1.6 million, Tuscany with 1.3 million and France with 190,000 
women.  
 
Prevalence of women receiving AED prescriptions in 2016 
Table 2 shows that the prevalence of women being prescribed AEDs in 2016 varied considerably 
both between and within countries with the prevalence being lowest in Emilia Romagna at 12.2 
(95%CI: 12.0-12.4) per 1000, higher in Tuscany and France (17.7 (17.5-18.0) and 19.1 (18.3-19.8) per 
1000 respectively) and highest in the UK at 29.0 (28.6 – 29.3) per 1000. The women in Italy had a 
mean age two years older than those in France and the UK , but those being prescribed AEDs had 
similar ages in all the databases.  
 
Table 2 also shows the prevalence of the ten most common medications in 2016. In contrast to the 
other regions 10.4 women per 1000 in the UK were prescribed gabapentin and 8.4 per 1000 were 
prescribed pregabalin - under 3 per 1000 women were prescribed either of these medications in the 
other regions apart from in France where 6.3 per 1000 women were prescribed pregabalin. 
Excluding prescriptions for gabapentin and pregabalin, valproate was the most frequently prescribed 
AED medication in all regions except for in the UK, where lamotrigine was more frequently 
prescribed, with the prevalence of valproate prescriptions varying from 6.6 per 1000 in Tuscany 
down to 2.7 per 1000 in the UK.  
 
Incidence of AED prescribing from 2007 – 2016 
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Figure 1a shows the changes in prescribing of AEDs to women who were first-time users for the ten 
years from 2007. The trends appear very different in the four regions, with large increases observed 
in the UK contrasting with large decreases in France. However, only a very small number of specific 
AEDs were responsible for these trends. When prescriptions of clonazepam, gabapentin and 
pregabalin were excluded, the trends were significantly decreasing in all regions by 9.6% (95%CI: 
8.3%-11.0%) per year (France), 7.5% (7.0%-8.0%) (Emilia Romagna), 7.1% (6.7%-7.6%) (Tuscany) and 
0.4% (0.2%-1.0%) (UK) (Figure 1b). The incidence of prescribing clonazepam, gabapentin and 
pregabalin in addition to the other eight most common AED medications according to year is given in 
Appendix 1 (Table A1 and Figure A1). 
 
Incidence of sodium valproate prescribing  
Figure 2 shows that the incidence of prescribing sodium valproate has fallen in all regions (2a) and 
that this fall is greater than the fall in other AEDs in France and the UK (2b) for the whole study 
period and for Emilia Romagna and Tuscany for the period from 2014. Table 3 shows that the odds 
of prescribing sodium valproate compared to any other AED (excluding clonazepam, gabapentin and 
pregabalin) decreased significantly from 2014 to 2016 and that this decrease was significantly 
greater from 2014 to 2016 than the annual changes from 2007 to 2016 in France and Italy – in the 
UK there had been a greater decrease in 2014 to 2016, but it was not statistically significant. 
Extremely similar estimates were obtained in the sensitivity analysis which included women with 
only a single AED prescription in the study period, resulting in the same degrees of statistical 
significance for France and Italy and the decrease in the UK being greater but not statistically 
significant (P=0.09). 
 
Incidence of prescribing sodium valproate according to age 
Figure 3 shows that the incidence of prescribing sodium valproate is highest in the oldest age groups 
(>40 years and 30-39 years) and that it is in these age groups that the incidence is decreasing the 
greatest. A figure illustrating the incidence of prescribing the eleven most common AED medications 
according to age is given in Appendix 1 (Figure A2). 
 
Incidence of AED prescribing according to indication 
In all regions/countries apart from France there was a large proportion of females for which the 
indication could not be confidently assumed : 56% in Tuscany, 37% in Emilia Romagna and 28% in 
the UK compared with 11% in France. Hence only the incidence of AED prescribing according to 
indication is given for France and the algorithm used is given in Appendix A. Table 4 shows that for 
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all AEDs 31% of prescriptions were for epilepsy and 40% for neuropathic pain, with some individual 
AED prescriptions being more likely to be for epilepsy (topiramate, carbamazepine, lamotrigine, 
levetiracetam, clobazam and oxcarbazepine) and valproate was more likely to be for bipolar 
disorders. The unknown indications were mainly for clonazepam prescriptions. Figure 4 shows that 
the incidence of valproate prescriptions is much greater for bipolar disorders than for epilepsy, apart 
from for women under 20 years of age. The incidence has decreased for both, with particularly large 
decreases for bipolar disorder following the warnings about sodium valproate in December 2014. 
 
DISCUSSION 
Study Findings 
This study analysed data from two regions in Italy, from France and the United Kingdom on 5.4 
million women aged 10-50 years between 1 January 2007 and 31 December 2016. In 2016 the 
United Kingdom had a much higher prevalence of AED prescribing than the other three regions (29 
per 1000 compared to 19.1, 17.7 and 12.2 respectively for France, Tuscany and Emilia Romagna). 
However, two drugs (pregabalin and gabapentin) were taken by over 60% of AED exposed women in 
the UK and when these two drugs were excluded the prevalence in the UK was 12.8 per 1000, more 
consistent with the other regions. In 2016 valproate was the most frequently prescribed AED in Italy, 
the second most frequent in France after pregabalin and the fourth in the United Kingdom after 
gabapentin, pregabalin and lamotrigine, with between 2.7 and 6.6 per 1000 women receiving more 
than 1 prescription in 2016. 
 
All regions did experience a reduction in the incidence of valproate prescribing during the whole 
study period. However, the results from fitting an interrupted time series model, indicated that in all 
regions there was a greater decline occurring post 2014 compared with pre 2014 for the prescription 
of valproate compared to the prescription of other AEDs. This decline was statistically significant in 
three of the regions. 
 
Strengths and Weaknesses 
Our study used electronic healthcare data and therefore exposure to AEDs was based on the 
issue/dispensing of a prescription. It was not possible to know whether the woman actually took the 
medicine and took it as and when instructed, although it is probably fair to assume that repeat 
prescribing of these products indicates actual use. Hence, in this study a woman was only defined as 
being exposed to an AED if she had at least 2 AED prescriptions over the study period. However this 
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did result in excluding a large proportion of single AED prescriptions, as has been observed in other 
studies.[5]  
 
None of the databases captured all AED prescriptions, but the proportions missed were thought to 
be small. For example, none captured prescriptions issued during in-patient hospital stays. In the UK, 
AED prescriptions issued by a specialist in secondary care were not captured, although the majority 
of AED prescribing, even if initiated by a specialist, would subsequently be undertaken by the GP. In 
France, AED prescriptions were not captured within the database if they were prescribed off label, 
which is an uncommon situation and in Italy a small number of AED products are not reimbursed by 
the Italian National Health Service.  No information on the dose of AEDs prescribed was analysed.  
 
A further weakness was that for three databases it was not possible to determine the indication for 
prescribing, partly related to the increasing number of indications for which AEDs are now 
prescribed [1, 2, 26] and an increase in the extent of off-label prescribing[27]. A study in the UK, 
using electronic healthcare data, found that 62% of prescriptions issued for pregabalin between 
2004 and 2009 did not have a diagnosis code corresponding to one of the approved indications[28]. 
The pattern of medications prescribed, particularly the increases in gabapentin and pregabalin, 
indicates that much of the increase in prescriptions was due to non-epilepsy indications, particularly 
pain treatments. This increase in AED prescriptions for non-epilepsy indications has been observed 
in Canada[2], Norway[29], Italy[6, 30], Denmark[5] and the US [31].  
 
The results in this study are consistent with those in other earlier studies; the regional variations 
observed in the extent of AED prescribing and the AEDs most commonly prescribed have been 
reported elsewhere [9, 10, 32], including a high prevalence of valproate prescribing in Italy between 
2005 and 2011 [30]. The decline in the incidence of valproate prescribing in the UK is comparable 
with that reported by an Irish study between 2008 and 2013 [33] and a study of prescriptions to 12-
18 year olds in the UK [34]. 
 
The dramatic decline in the incidence of clonazepam prescribing observed in France is explained by 
changes in the rules on prescribing that came into effect between September 2011 and January 
2012, following the observation of misuse and abuse of the product. Since September 2011, 
clonazepam can only be prescribed on a special prescription form that is usually specific to the 
prescribing of narcotics and controlled substances. Since January 2011 the initiation of clonazepam 
treatment has been restricted to neurologists and paediatricians.  
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The relatively high levels of prescriptions for gabapentin and pregabalin, usually for neuropathic pain 
and the recent increases particularly in the UK and to some extent Tuscany have been reported 
earlier in Italy [3, 30] [6] the UK [9] and Norway[29]. Such increases have also occurred in non-
European countries such as Canada [2] and Australia [7]. These increases together with evidence 
that these AEDs have the potential for abuse [35], mean that the utilisation of these products 
requires future monitoring. In addition, more information is needed on the safety in pregnancy of 
these new AEDs, particularly for pregabalin. Two recent studies have produced conflicting results on 
the teratogenicity of pregabalin in the first trimester; the first was a multicentre study from the 
European Network of Teratology Information Services which reported an odds ratio (OR) = 3.0 
(95%CI: 1.2-7.9) for pregabalin use in pregnancy and major congenital malformations in the fetus 
[36]. The second study using the US Medicaid Analytic Extract (MAX) reported a relative risk (RR) = 
1.16 (95%CI: 0.81-1.67) for pregabalin use in pregnancy and major congenital malformations in the 
fetus after propensity score adjustment [37]. A recent review included nine studies on the safety of 
gabapentin use during pregnancy and concluded that there was no evidence of an increased risk of 
major congenital anomalies, but the studies were all small [38].  
 
 
Implications 
There is some evidence in the regions studied of a greater reduction in the prescribing of sodium 
valproate compared to other AEDs since 2014 compared with before 2014. However it is still of 
concern that in 2016 after pregabalin and gabapentin, valproate was the most commonly prescribed 
AED in all regions except for the UK (where lamotrigine was more common) with the prevalences of 
valproate prescriptions varying from 6.6 per 1000 in Tuscany down to 2.7 per 1000 in the UK. Much 
of the decrease in the incidence of prescribing valproate is occurring in older women, who may have 
already completed their families. In February 2018 the European Medicines Agency’s PRAC 
recommended that sodium valproate must no longer be prescribed to women or girls of childbearing 
potential unless they are on the pregnancy prevention programme (PPP). The success of this could 
be monitored by studies similar to this one, but due to the differences observed across the regions 
studied here, in order to obtain a valid European measure of effect, more than four regions should 
be included. 
 
This study has demonstrated that, in addition to epilepsy, AEDs are now being increasingly 
prescribed for other indications which means that data to evaluate the safety of AEDs should cover 
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the full range of indications in addition to disease specific registries. It is important that all 
prescribing advice and warnings in addition to any interventions are made apparent to all potentially 
relevant prescribers, medical specialties, pharmacists and AED users and are not restricted to having 
the emphasis put on a particular indication.  
 
The rapid increases observed in the prescribing of gabapentin and pregabalin in women of  
childbearing age and the lack of evidence of their safety during pregnancy means that further 
investigations into the use and safety in pregnancy of these medications should be performed. 
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Table 1: An overview of the databases contributing to the study 
Country/Region 
 
 Italy -   
Tuscany 
Italy - 
Emilia Romagna 
France 
 
United Kingdom 
 
Involves database 
record linkage 
Yes 
 
Yes 
 
Yes 
 
No 
 
Population base 3,700,000 4,200,000 680,000 (1/97 of 
French 
population) 
5,000,000  
(~8% of the UK 
population) 
Database for live & 
stillbirth pregnancy 
identification 
 
 
Certificate of 
Delivery 
Assistance 
(CeDAP) 
Hospital 
Discharges 
Registry 
 
Certificate of 
Delivery 
Assistance 
(CeDAP) 
 
 
Echantillon 
Généraliste des 
bénéficiaires 
(EGB) 3 
Clinical Practice 
Research 
Datalink 
 (CPRD) 
Database for 
pregnancy loss 
identification 
 
Discharges for 
Induced 
Terminations & 
Spontaneous 
Abortions. 
Hospital 
Discharges 
Registry 
 
Not available 
 
EGB, French 
Health 
Insurance 
System  
and PMSI 
 
CPRD 
 
  
Database for medicine  
use data 
 
Tuscany 
Prescription 
Database 
(TPD) 
Emilia-Romagna 
Prescription 
Database (ERPD) 
French Health 
Insurance 
System  
Database 
CPRD 
Source for medicine 
use data 
 
Pharmacy 
dispensing and 
Healthcare 
facilities 
dispensing 
(except 
inpatient 
exposure)2 
Pharmacy  
dispensing and 
Healthcare 
facilities 
dispensing 
(except 
inpatient 
exposure)2 
 
Pharmacy  
Dispensing 
 
GP practice 
prescribing1 
 
 
Start of first data 
collection 
2003 
 
2003 
 
2005 
 
1987 
 
Capture outpatient 
prescribing 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Capture inpatient 
prescribing 
No 
 
No 
 
No 
 
Some 
 
 
 
1 Including nurse prescribers working within the GP practice 
2 Including only products reimbursed by the Italian National Health Service and excluding those 
dispensed to outpatients in a hospital pharmacy 
3 EGB includes data from French Health insurance system & Hospital Medical Information System 
databases (PMSI) 
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Table 2: Numbers and prevalence of women aged 10 to 50 years with > 1 prescription for an AED 
during 2016 according to region and ten most common AEDs 
 
 Tuscany Emilia Romagna France UK 
Number of women 
in database in 2016 
[Mean age in years] 
989,673 
[33.0] 
1,210,223 
[33.2] 
138,566 
[31.4] 
766,304 
[31.2] 
Number of women 
with >1 AED 
prescriptions in 
2016 
[Mean age in years] 
17,559 
[37.7] 
14,733 
[37.8] 
2,641 
[38.3] 
22,197 
[37.7] 
Prevalence per 1000 women (95% CI)   
Any AED  17.7  
(17.5 – 18.0) 
12.2 
(12.0 - 12.4) 
19.1 
(18.3 - 19.8) 
29.0 
(28.6 - 29.3) 
Gabapentin 1.9 (1.8 – 2.0) 1.1 (1.0 - 1.2) 1.8 (1.6 - 2.1) 10.4 (10.2 - 10.6) 
Pregabalin 2.9 (2.8 – 3.0) 1.7 (1.6 - 1.7) 6.3 (5.9 - 6.7) 8.4 (8.2 - 8.6) 
Valproate 6.6 (6.5 - 6.8) 3.1 (3.0 - 3.2) 4.4 (4.1 - 4.8) 2.7 (2.6 - 2.8) 
Topiramate 2.2 (2.1 - 2.3) 1.6 (1.5 - 1.6) 1.7 (1.5 - 1.9) 2.5 (2.4 - 2.6) 
Clonazepam 1.5 (1.4 - 1.6) 1.7 (1.7 - 1.8) 0.8 (0.7 – 1.0) 0.8 (0.7 - 0.8) 
Carbamazepine 2.0 (1.9 - 2.1) 1.5 (1.5 - 1.6) 1.3 (1.1 - 1.5) 2.5 (2.4 - 2.6) 
Lamotrigine 1.9 (1.8 – 2.0) 1.9 (1.8 - 1.9) 3.1 (2.9 - 3.4) 4.3 (4.1 - 4.4) 
Levetiracetam 1.2 (1.2 - 1.3) 1.3 (1.3 - 1.4) 1.7 (1.5 - 1.9) 2.2 (2.1 - 2.3) 
Clobazam - 0.1 (0.1 - 0.1) 1.6 (1.4 - 1.8) 0.7 (0.6 - 0.7) 
Oxcarbazepine 0.9 (0.8 - 0.9) 0.6 (0.5 - 0.6) 0.5 (0.3 - 0.6) 0.1 (0.1 - 0.1) 
 
 
Table 3: Odds ratio of prescribing sodium valproate compared to another AED (excluding 
clonazepam, gabapentin and pregabalin) per year for each region : comparing 2007-2013 with 
2014-2016   
 
 Odds ratio of prescribing sodium valproate 
compared to another AED per year 
 
Ratio of OR 
 2014-2016 vs  
2007-2013 
P values for 
comparison 
of odds 
ratios  2007-2013 2014-2016 
Emilia 
Romagna 
1.01 ( 1.00 - 1.03 ) 0.84 ( 0.78 - 0.91 ) 0.83 (0.76 – 0.90) < 0.001 
France 0.94 ( 0.90 - 0.98 ) 0.72 ( 0.56 - 0.91 ) 0.77 (0.60 – 0.98) 0.033 
Tuscany 1.05 ( 1.04 - 1.06 ) 0.85 ( 0.80 - 0.91 ) 0.81 (0.76 – 0.86) < 0.001 
UK 0.87 ( 0.85 - 0.89 ) 0.80 ( 0.69 - 0.92 ) 0.92 (0.80 – 1.06) 0.262 
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Table 4 : Percentage of women with > 1 prescription for an AED for the first time from 2007-2016 
according to indication in France (Totals may be above 100% as some women are prescribed 
medications for multiple reasons). 
 
  Percentage of women (%) 
  Number 
of 
women Epilepsy Bipolar Anxiety 
Neuropathic 
pain Migraine 
Other / 
Unknown 
Any AED  7382 31 16 4 40 1 11 
Gabapentin 418 23 2 2 73 0 0 
Pregabalin 2584 15 2 4 79 0 0 
Valproate 1059 29 81 0 0 0 0 
Topiramate 388 80 3 1 0 16 0 
Clonazepam 1874 20 6 0 37 0 43 
Carbamazepine 214 76 20 1 3 0 0 
Lamotrigine 243 67 34 0 0 0 0 
Levetiracetam 189 100 0 0 0 0 0 
Clobazam 579 67 6 25 0 0 3 
Oxcarbazepine 41 100 7 0 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
Figure legends: 
 
Figure 1: Trends in the incidence of first prescriptions in the four regions from 2007 to 2016 (a) 
Incidence of any AED and (b) incidence of any AED excluding clonazepam, gabapentin and 
pregabalin.  
 
Figure 2: Incidence of prescribing sodium valproate according to year of first prescription and region 
(a) per 10,000 women and (b) expressed as a proportion of all AEDs (excluding clonazepam, 
gabapentin and pregabalin). 
 
Figure 3: Incidence of sodium valproate prescriptions per 10,000 person years according to age at 
first prescription and year of prescription in the four regions 
 
Figure 4: Incidence of prescriptions for valproate according to year at first prescription, indication 
and age in France 
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